keyword
MENU ▼
Read by QxMD icon Read
search

Aurora A kinase clinical trials

keyword
https://www.readbyqxmd.com/read/28389630/identification-of-small-molecule-inhibitors-of-the-aurora-a-tpx2-complex
#1
Italia Anna Asteriti, Frederick Daidone, Gianni Colotti, Serena Rinaldo, Patrizia Lavia, Giulia Guarguaglini, Alessandro Paiardini
Aurora kinases are a family of cell division regulators that govern the correct assembly of a bipolar mitotic spindle and the fidelity of chromosome segregation. Their overexpression is associated with genomic instability and aneuploidy, and is frequently observed in cancer. Accordingly, competitive inhibitors targeting Aurora kinase activity at the ATP-binding site are being investigated for therapeutic purposes. Despite promising pre-clinical data, these molecules display moderate effects in clinical trials and incomplete selectivity, either against distinct family members, or other kinases...
March 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28207834/a-cyclin-dependent-kinase-inhibitor-dinaciclib-in-preclinical-treatment-models-of-thyroid-cancer
#2
Shu-Fu Lin, Jen-Der Lin, Chuen Hsueh, Ting-Chao Chou, Richard J Wong
BACKGROUND: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer. MATERIALS AND METHODS: Seven cell lines originating from three pathologic types of thyroid cancer (papillary, follicular and anaplastic) were studied. The cytotoxicity of dinaciclib was measured using a lactate dehydrogenase assay. The expression of proteins associated with cell cycle and apoptosis was assessed using Western blot analysis and immunofluorescence microscopy...
2017: PloS One
https://www.readbyqxmd.com/read/28147331/aurora-a-kinase-inhibition-enhances-oncolytic-herpes-virotherapy-through-cytotoxic-synergy-and-innate-cellular-immune-modulation
#3
Mark A Currier, Les Sprague, Tilat A Rizvi, Brooke Nartker, Chun-Yu Chen, Pin-Yi Wang, Brian J Hutzen, Meghan R Franczek, Ami V Patel, Katherine E Chaney, Keri A Streby, Jeffrey A Ecsedy, Joe Conner, Nancy Ratner, Timothy P Cripe
Malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma models respond to the investigational small molecule Aurora A kinase inhibitor, alisertib. We previously reported that MPNST and neuroblastomas are also susceptible to oncolytic herpes virus (oHSV) therapy. Herein, we show that combination of alisertib and HSV1716, a virus derived from HSV-1 and attenuated by deletion of RL1, exhibits significantly increased antitumor efficacy compared to either monotherapy. Alisertib and HSV1716 reduced tumor growth and increased survival in two xenograft models of MPNST and neuroblastoma...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28127048/cell-cycle-proteins-as-promising-targets-in-cancer-therapy
#4
REVIEW
Tobias Otto, Piotr Sicinski
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant activity of various cell cycle proteins. Therefore, cell cycle regulators are considered attractive targets in cancer therapy. Intriguingly, animal models demonstrate that some of these proteins are not essential for proliferation of non-transformed cells and development of most tissues. By contrast, many cancers are uniquely dependent on these proteins and hence are selectively sensitive to their inhibition. After decades of research on the physiological functions of cell cycle proteins and their relevance for cancer, this knowledge recently translated into the first approved cancer therapeutic targeting of a direct regulator of the cell cycle...
January 27, 2017: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/28101375/aurora-a-promotes-the-establishment-of-spindle-assembly-checkpoint-by-priming-the-haspin-aurora-b-feedback-loop-in-late-g2-phase
#5
Fazhi Yu, Ya Jiang, Lucy Lu, Mimi Cao, Yulong Qiao, Xing Liu, Dan Liu, Terry Van Dyke, Fangwei Wang, Xuebiao Yao, Jing Guo, Zhenye Yang
Aurora-A kinase functions mainly in centrosome maturation, separation and spindle formation. It has also been found to be amplified or overexpressed in a range of solid tumors, which is linked with tumor progression and poor prognosis. Importantly, Aurora-A inhibitors are being studied in a number of ongoing clinical trials. However, whether and how Aurora-A has a role in the regulation of the mitotic checkpoint is controversial. Additionally, the function of nuclear-accumulated Aurora-A in late G2 phase is not clear...
2017: Cell Discovery
https://www.readbyqxmd.com/read/27905678/a-phase-i-ii-trial-of-at9283-a-selective-inhibitor-of-aurora-kinase-in-children-with-relapsed-or-refractory-acute-leukemia-challenges-to-run-early-phase-clinical-trials-for-children-with-leukemia
#6
B Vormoor, G J Veal, M J Griffin, A V Boddy, J Irving, L Minto, M Case, U Banerji, K E Swales, J R Tall, A S Moore, M Toguchi, G Acton, K Dyer, C Schwab, C J Harrison, J D Grainger, D Lancaster, P Kearns, D Hargrave, J Vormoor
Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27502708/phase-ii-study-of-mln8237-alisertib-in-advanced-metastatic-sarcoma
#7
M A Dickson, M R Mahoney, W D Tap, S P D'Angelo, M L Keohan, B A Van Tine, M Agulnik, L E Horvath, J S Nair, G K Schwartz
BACKGROUND: Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel oral adenosine triphosphate-competitive AURKA inhibitor. PATIENTS AND METHODS: This Cancer Therapy Evaluation Program-sponsored phase II study of alisertib was conducted through the Alliance for Clinical Trials in Oncology (A091102). Patients were enrolled into histology-defined cohorts: (i) liposarcoma, (ii) leiomyosarcoma, (iii) undifferentiated sarcoma, (iv) malignant peripheral nerve sheath tumor, or (v) other...
October 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27496137/pharmacological-profile-of-bi-847325-an-orally-bioavailable-atp-competitive-inhibitor-of-mek-and-aurora-kinases
#8
Patrizia Sini, Ulrich Gürtler, Stephan K Zahn, Christoph Baumann, Dorothea Rudolph, Rosa Baumgartinger, Eva Strauss, Christian Haslinger, Ulrike Tontsch-Grunt, Irene C Waizenegger, Flavio Solca, Gerd Bader, Andreas Zoephel, Matthias Treu, Ulrich Reiser, Pilar Garin-Chesa, Guido Boehmelt, Norbert Kraut, Jens Quant, Günther R Adolf
Although the MAPK pathway is frequently deregulated in cancer, inhibitors targeting RAF or MEK have so far shown clinical activity only in BRAF- and NRAS-mutant melanoma. Improvements in efficacy may be possible by combining inhibition of mitogenic signal transduction with inhibition of cell-cycle progression. We have studied the preclinical pharmacology of BI 847325, an ATP-competitive dual inhibitor of MEK and Aurora kinases. Potent inhibition of MEK1/2 and Aurora A/B kinases by BI 847325 was demonstrated in enzymatic and cellular assays...
October 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27496133/barasertib-azd1152-a-small-molecule-aurora-b-inhibitor-inhibits-the-growth-of-sclc-cell-lines-in-vitro-and-in-vivo
#9
Barbara A Helfrich, Jihye Kim, Dexiang Gao, Daniel C Chan, Zhiyong Zhang, Aik-Choon Tan, Paul A Bunn
Small-cell lung cancer (SCLC) cells have rapid proliferation, universal Rb inactivation, and high rates of MYC family amplification, making aurora kinase inhibition a natural target. Preclinical studies have demonstrated activity for Aurora A and pan-Aurora inhibitors with some relationship to MYC family expression. A clinical trial showed activity for an Aurora kinase A inhibitor, but no biomarkers were evaluated. We screened a panel of 23 SCLC lines with and without MYC family gene amplification or high MYC family gene expression for growth inhibition by the highly potent, selective aurora kinase B inhibitor barasertib...
October 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27235164/combination-of-eribulin-and-aurora-a-inhibitor-mln8237-prevents-metastatic-colonization-and-induces-cytotoxic-autophagy-in-breast-cancer
#10
Varvara K Kozyreva, Anna A Kiseleva, Ryan J Ice, Brandon C Jones, Yuriy V Loskutov, Fatimah Matalkah, Matthew B Smolkin, Kristina Marinak, Ryan H Livengood, Mohamad A Salkeni, Sijin Wen, Hannah W Hazard, Ginger P Layne, Callee M Walsh, Pamela S Cantrell, Greg W Kilby, Sricharan Mahavadi, Neal Shah, Elena N Pugacheva
Recent findings suggest that the inhibition of Aurora A (AURKA) kinase may offer a novel treatment strategy against metastatic cancers. In the current study, we determined the effects of AURKA inhibition by the small molecule inhibitor MLN8237 both as a monotherapy and in combination with the microtubule-targeting drug eribulin on different stages of metastasis in triple-negative breast cancer (TNBC) and defined the potential mechanism of its action. MLN8237 as a single agent and in combination with eribulin affected multiple steps in the metastatic process, including migration, attachment, and proliferation in distant organs, resulting in suppression of metastatic colonization and recurrence of cancer...
August 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27213815/a-myc-aurora-kinase-a-protein-complex-represents-an-actionable-drug-target-in-p53-altered-liver-cancer
#11
Daniel Dauch, Ramona Rudalska, Giacomo Cossa, Jean-Charles Nault, Tae-Won Kang, Torsten Wuestefeld, Anja Hohmeyer, Sandrine Imbeaud, Tetyana Yevsa, Lisa Hoenicke, Tatu Pantsar, Przemyslaw Bozko, Nisar P Malek, Thomas Longerich, Stefan Laufer, Antti Poso, Jessica Zucman-Rossi, Martin Eilers, Lars Zender
MYC oncoproteins are involved in the genesis and maintenance of the majority of human tumors but are considered undruggable. By using a direct in vivo shRNA screen, we show that liver cancer cells that have mutations in the gene encoding the tumor suppressor protein p53 (Trp53 in mice and TP53 in humans) and that are driven by the oncoprotein NRAS become addicted to MYC stabilization via a mechanism mediated by aurora kinase A (AURKA). This MYC stabilization enables the tumor cells to overcome a latent G2/M cell cycle arrest that is mediated by AURKA and the tumor suppressor protein p19(ARF)...
July 2016: Nature Medicine
https://www.readbyqxmd.com/read/27209210/aurora-kinase-a-expression-predicts-platinum-resistance-and-adverse-outcome-in-high-grade-serous-ovarian-carcinoma-patients
#12
Chiara Mignogna, Nicoletta Staropoli, Cirino Botta, Carmela De Marco, Antonia Rizzuto, Michele Morelli, Annalisa Di Cello, Renato Franco, Caterina Camastra, Ivan Presta, Natalia Malara, Angela Salvino, Pierfrancesco Tassone, Pierosandro Tagliaferri, Tullio Barni, Giuseppe Donato, Anna Di Vito
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months)...
May 21, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27147567/continuous-anti-angiogenic-therapy-after-tumor-progression-in-patients-with-recurrent-high-grade-epithelial-ovarian-cancer-phase-i-trial-experience
#13
Ming-Mo Hou, Zhijie Wang, Filip Janku, Sarina Piha-Paul, Aung Naing, David Hong, Shannon Westin, Robert L Coleman, Anil K Sood, Apostolia M Tsimberidou, Vivek Subbiah, Jennifer Wheler, Ralph Zinner, Karen Lu, Funda Meric-Bernstam, Siqing Fu
High-grade epithelial ovarian cancer (HG-EOC) is the most lethal gynecologic malignancy worldwide Once patients develop chemoresistance, effective novel strategies are required to improve prognosis We analyzed characteristics and outcomes of 242 consecutive patients with HG-EOC participating in 94 phase I clinical trials at The University of Texas MD Anderson Cancer Center. Baseline lactate dehydrogenase levels, albumin levels, and number of metastatic sites were independent predictors of overall survival (OS)...
June 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27101098/clinical-outcome-of-treatment-with-serine-threonine-kinase-inhibitors-in-recurrent-epithelial-ovarian-cancer-a-systematic-review-of-literature
#14
REVIEW
Marcia A Ciccone, Asaf Maoz, Jennifer K Casabar, Hiroko Machida, Seiji Mabuchi, Koji Matsuo
INTRODUCTION: While serine-threonine kinases (STK) are attractive therapeutic targets in epithelial ovarian cancer, clinical outcomes of STK inhibitors in the management of recurrent disease have not been completely described. AREAS COVERED: A systematic literature review of published clinical studies on STK inhibitors targeting mTOR, MAPK, and aurora kinase pathways in recurrent epithelial ovarian cancer was conducted, revealing 18 clinical trials (497 patients)...
July 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27082996/otssp167-abrogates-mitotic-checkpoint-through-inhibiting-multiple-mitotic-kinases
#15
Wenbin Ji, Christopher Arnst, Aaron R Tipton, Michael E Bekier, William R Taylor, Tim J Yen, Song-Tao Liu
OTSSP167 was recently characterized as a potent inhibitor for maternal embryonic leucine zipper kinase (MELK) and is currently tested in Phase I clinical trials for solid tumors that have not responded to other treatment. Here we report that OTSSP167 abrogates the mitotic checkpoint at concentrations used to inhibit MELK. The abrogation is not recapitulated by RNAi mediated silencing of MELK in cells. Although OTSSP167 indeed inhibits MELK, it exhibits off-target activity against Aurora B kinase in vitro and in cells...
2016: PloS One
https://www.readbyqxmd.com/read/26999067/an-update-on-the-pharmacokinetics-and-pharmacodynamics-of-alisertib-a-selective-aurora-kinase-a-inhibitor
#16
REVIEW
Cameron T Durlacher, Zhi-Ling Li, Xiao-Wu Chen, Zhi-Xu He, Shu-Feng Zhou
Human Aurora kinases, including Aurora kinase A (AURKA), B (AURKB), and C (AURKC), play an essential role in mitotic events such as monitoring of the mitotic checkpoint, creation of bipolar mitotic spindle and alignment of centrosomes on it, also regulating centrosome separation, bio-orientation of chromosomes and cytokinesis. AURKA and AURKB are key regulators of mitosis and centrosome via polymerizing microfilaments and controlling chromatid segregation. In particular, AURKA plays critical roles in the regulation of mitotic entry, centrosome function, bipolar spindle assembly, and chromosome segregation...
June 2016: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/26967327/overview-of-current-treatment-options-and-investigational-targeted-therapies-for-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck
#17
Matthew Zibelman, Ranee Mehra
Patients with squamous cell carcinoma of the head and neck (SCCHN) typically present with locally advanced (LA) stage III or IV disease and are treated with combined-modality therapy with chemotherapy, radiotherapy, and surgery (if resectable). These aggressive, upfront treatment measures are often associated with substantial morbidity, and about half the patients develop locoregional or distant recurrences. Thus, new therapeutic strategies are needed that offer similar efficacy benefits with less toxicity...
August 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26962685/overcoming-mitf-conferred-drug-resistance-through-dual-aurka-mapk-targeting-in-human-melanoma-cells
#18
G Pathria, B Garg, V Borgdorff, K Garg, C Wagner, G Superti-Furga, S N Wagner
MITF (microphthalmia-associated transcription factor) is a frequently amplified lineage-specific oncogene in human melanoma, whose role in intrinsic drug resistance has not been systematically investigated. Utilizing chemical inhibitors for major signaling pathways/cellular processes, we witness MITF as an elicitor of intrinsic drug resistance. To search kinase(s) targets able to bypass MITF-conferred drug resistance, we employed a multi-kinase inhibitor-directed chemical proteomics-based differential affinity screen in human melanocytes carrying ectopic MITF overexpression...
March 10, 2016: Cell Death & Disease
https://www.readbyqxmd.com/read/26755072/atypical-teratoid-rhabdoid-tumors-current-concepts-advances-in-biology-and-potential-future-therapies
#19
REVIEW
Michael C Frühwald, Jaclyn A Biegel, Franck Bourdeaut, Charles W M Roberts, Susan N Chi
Atypical teratoid/rhabdoid tumor (AT/RT) is the most common malignant CNS tumor of children below 6 months of age. The majority of AT/RTs demonstrate genomic alterations in SMARCB1 (INI1, SNF5, BAF47) or, to a lesser extent, SMARCA4 (BRG1) of the SWItch/sucrose nonfermentable chromatin remodeling complex. Recent transcription and methylation profiling studies suggest the existence of molecular subgroups. Thus, at the root of these seemingly enigmatic tumors lies a network of factors related to epigenetic regulation, which is not yet completely understood...
June 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26622997/recent-advances-in-the-development-of-aurora-kinases-inhibitors-in-hematological-malignancies
#20
REVIEW
Iqra Choudary, Paul M Barr, Jonathan Friedberg
Over the last two decades, since the discovery of Drosophila mutants in 1995, much effort has been made to understand Aurora kinase biology. Three mammalian subtypes have been identified thus far which include the Aurora A, B and C kinases. These regulatory proteins specifically work at the cytoskeleton and chromosomal structures between the kinetochores and have vital functions in the early phases of the mitotic cell cycle. Today, there are multiple phase I and phase II clinical trials as well as numerous preclinical studies taking place looking at Aurora kinase inhibitors in both hematologic and solid malignancies...
December 2015: Therapeutic Advances in Hematology
keyword
keyword
111491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"